Table 2.
Analgesic medication immediately prior to treatment with tapentadol PR.
| Aged >65 years (n = 752) | Aged ≤65 years (n = 282) | |
|---|---|---|
| Strong opioidsa | 353 (46.9%) | 113 (40.1%) |
| Fentanyl (transdermal) | 129 (17.2%) | 36 (12.8%) |
| Oxycodone/naloxone | 74 (9.8%) | 30 (10.6%) |
| Oxycodone | 61 (8.1%) | 26 (9.2%) |
| Buprenorphine | 56 (7.5%) | 9 (3.2%) |
| Morphine | 37 (4.9%) | 19 (6.7%) |
| Hydromorphone | 33 (4.4%) | 9 (3.2%) |
| Other | 1 (0.1%) | 1 (0.4%) |
| Weak opioidsa | 396 (52.7%) | 166 (58.9%) |
| Tramadol | 214 (28.5%) | 100 (35.5%) |
| Tilidine/naloxone | 200 (26.6%) | 76 (27%) |
| Other/not specified | 1 (0.1%) | 0 |
| Nonopioidsa | 641 (85.2%) | 247 (87.6%) |
| Nonsteroidal anti-inflammatory drugs | 468 (62.2%) | 199 (70.6%) |
| Metamizole | 330 (43.9%) | 105 (37.2%) |
| Muscle relaxants | 115 (15.3%) | 64 (22.7%) |
| Paracetamol | 62 (8.2%) | 34 (12.1%) |
| Other/not specified | 34 (4.5%) | 9 (3.2%) |
Data are number of patients (%); amultiple responses permitted. PR, prolonged release.